China Human Vaccine Industry Report, 2011-2012

NEW YORK, May 28, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

http://www.reportlinker.com/p0512477/China-Human-Vaccine-Industry-Report-2011-2012.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_

After decades of development, China has become one of the major producer and consumers of human vaccine around the world. In 2011, human vaccine manufacturers numbered 38 in China and the lot release quantity of human vaccine footed up to roughly 770 million person-portions, with market size reaching around RMB1 billion. Moreover, being restricted by the barriers such as vaccine industry policy, technology and capital, it is not easy for companies to set foot in this field and the industry has been with high profitability as a whole. From 2007 to 2011, the gross margin of vaccine business of major manufacturers basically maintained above 60%, and some enterprises such as Walvax Biotechnology and Liaoning Chengda even enjoyed the gross margin of as high as 90% or so.

Although Japanese Encephalitis Vaccine, Hepatitis A Vaccine and Influenza Vaccine have been exported to other countries, they are mainly consumed in China. However, China's vaccine supervisory system was approved by the WHO in March 2011, which may eventually open the door for Chinese vaccines to be distributed globally. In 2011, Tiantan Biological signed a cooperation agreement on oral polio vaccine (OPV) with Bill & Melinda Gates Foundation, according to which, the company will annually supply 160 million OPV doses for United Nations International Children's Emergency Fund (UNICEF) at the negotiated price after its Yizhuang-based Vaccine Workshop is built and has its vaccines "pre-qualified" by the WHO.

The report not only highlights the domestic and international operating environment, overall situation and market supply & demand of Chinese human vaccine industry, and market segments and prospects of 10 vaccines, but also analyzes the competition pattern, as well as operation, advantages and new product R&D dynamics of 11 human vaccine manufacturers.

Affected by the economic level, the national vaccination policy and the public awareness of epidemic prevention, the real vaccination is still mainly concentrated in EPI vaccine. The ratio between the lot release quantity of EPI and Extra EPI vaccine was 3:1 in 2010 which was raised to 4:1 in 2011, similar to that in 2009. Additionally, EPI vaccine market in China is almost monopolized by state-run enterprises represented by CNBG Tiantan Biological and Biological Products Institutes in Changchu, Chengdu, Wuhan, Shanghai and Lanzhou, and Institute of Medical Biology Chinese Academy of Medical Sciences. In 2011, the state-owned companies accounted for 86.4% market share (by lot release quantity), and even occupied more than 99% market share in OPV segment.

Along with the gradual easing of access to vaccine market, the private firms enjoy the rising share in Extra EPI vaccine market. In 2011, in terms of lot release quantity, private enterprises made up as high as 52% market share and occupied 98.9% share in human Rabies Vaccine market. Meanwhile, the foreign companies maintain 15-20% market share (by lot release) by virtue of their technologies and product advantages. Stimulated by the robust demand for vaccines from Chinese market, five vaccine giants including GSK, Pfizer, Sanofi Pasteur, Merk and Novartis aggressively expand their business in China.

In January 2011, Merk acquired 100% equities of Beijing Skywing Bio-Tech, a player in the vaccine upstream sector. In March 2011, Novartis' acquisition on 85% stake of Zhejiang Tianyuan was approved. In June 2011, GSK projected ?24 million for 51% shares of GlaxoSmithKline-Neptunus. At the end of 2011, the joint venture between GSK and Walvax Biotechnology---GSK-Walvax Influenza Vaccine (Split Virion) Project was in the civil construction phase.

1.1 Definition & Classification

1.2 Industry Chain

2. China Human Vaccine Industry 2.1 Overview2.2 Operating Environment2.2.1 International Market2.2.2 Policy Environment 2.2.3 Biopharmaceutical Market 2.3 Status Quo2.4 Supply & Demand2.5 Competition Pattern2.6 Prospect & Dynamics2.7 Sales Channel

3. Human Vaccine Market Segments in China

3.1 Hepatitis B Vaccine

3.1.1 Supply & Demand

3.1.2 Competition Pattern

3.1.3 Market Price

3.2 Meningococcal Vaccines

3.2.1 Supply & Demand

3.2.2 Competition Pattern

3.2.3 Market Price

3.2.4 Market Forecast

3.3 Hepatitis A Vaccine

3.3.1 Supply & Demand

3.3.2 Competition Pattern

3.3.3 Market Price

3.3.4 Market Forecast

3.4 Influenza Vaccine

3.4.1 Supply & Demand

3.4.2 Competition Pattern

3.4.3 Market Price

3.5 Hib Vaccine

3.5.1 Supply & Demand

3.5.2 Competition Pattern

3.5.3 Market Price

3.5.4 Market Forecast

3.6 Rabies Vaccine

3.6.1 Supply & Demand

3.6.2 Competition Pattern

3.6.3 Market Price

3.6.4 Market Forecast

3.7 Varicella Vaccine

3.7.1 Supply & Demand

3.7.2 Competition Pattern

3.7.3 Market Price

3.8 Pneumococcal Vaccine

3.8.1 Supply & Demand

3.8.2 Competition Pattern

3.8.3 Market Price

3.9 DTP Vaccine

3.9.1 Supply & Demand

3.9.2 Competition Pattern

3.9.3 Market Dynamics & Forecast

3.10 Poliomyelitis Vaccine

3.10.1 Supply & Demand

3.10.2 Competition Pattern

4. Import and Export of Human Vaccine in China4.1 Export4.1.1 Export Volume & Value4.1.2 Export Destinations4.2 Import4.1.1 Import Volume & Value4.2.2 Country/Region of origin

5. Major Human Vaccine Manufacturers in China

5.1 China National Biotec Group

5.1.1 Beijing Tiantan Biological Products Co., Ltd

5.2 Hualan Biological Engineering Inc.

5.2.1 Profile

5.2.2 Operation

5.2.3 Revenue Structure

5.2.4 Gross Margin

5.2.5 Client and Supplier

5.2.6 R&D and Investment

5.2.7 Vaccine Business

5.3 Chongqing Zhifei Biological Products Co., Ltd.

5.3.1 Profile

5.3.2 Operation

5.3.3 Revenue Structure

5.3.4 Gross Margin

5.3.5 Client

5.3.6 R&D and Investment

5.4 Walvax Biotechnology Co., Ltd.

5.4.1 Profile

5.4.2 Operation

5.4.3 Revenue Structure

5.4.4 Gross Margin

5.4.5 Client and Supplier

5.4.6 R&D and Investment

5.5 Sinovac Biotech Ltd.

5.5.1 Profile

5.5.2 Operation

5.5.3 Revenue Structure

5.5.4 Gross Margin

5.5.5 R&D and Investment

5.6 Liaoning Chengda Co., Ltd.

5.6.1 Profile

5.6.2 Operation

5.6.3 Revenue Structure

5.6.4 Gross Margin

5.6.5 Client

5.6.6 Vaccine Business

5.7 Changchun BCHT Biotechnology Co., Ltd.

5.7.1 Profile

5.7.2 Operation

5.8 Changchun Changsheng Life Sciences Limited

5.8.1 Profile

5.8.2 Operation

5.9 Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd.

5.9.1 Profile

5.9.2 Operation

5.10 Shenzhen Kangtai Biological Products Co. Ltd.

5.10.1 Profile

5.10.2 Operation

5.11 Dalian Hissen Bio-Pharm Co., Ltd.

5.11.1 Profile

5.11.2 Operation

Vaccine Industry Chain

EPI Human Vaccine Varieties in China, 2011

Global Human Vaccine Market Size, 2007-2011

Sales of Global Top 5 Human Vaccine Manufacturers, 2007-2011

R &D of New Vaccines Worldwide, 2009-2012

Main Mergers & Acquisitions in the Vaccine Industry Worldwide, 2005-2011

Policies Concerning Vaccine Industry in China

Sales Value and Total Profit of Biological & Biochemical Product Industry in China, 2008- 2011

Market Size of Human Vaccine in China, 2007-2011

Major Human Vaccine Varieties and Producers in China

Gross Margin of Major Human Vaccine Manufacturers in China, 2007-2011

Lot Release Quantity and Proportion of EPI and Extra EPI Vaccines in China, 2007-2011

EPI Human Vaccine Market Share in China by Lot Release Quantity, 2007-2011

Extra EPI Human Vaccine Market Share in China by Lot Release Quantity, 2007-2011

R &D of New Human Vaccine in China by the End of Mar. 2012

Events Related to Vaccine Business of Foreign Corporations in China, 2011-2012

Vaccine Distribution Channel in China

Lot Release Quantity of Hepatitis B Vaccine in China by Dosage Form, 2007-2011

Hepatitis B Vaccine (CHO Cell) Suppliers and Lot Release Quantity in China, 2007-2011

Hepatitis B Vaccine (Yeast) Suppliers and Lot Release Quantity in China, 2007-2011

Market Prices of Hepatitis B Vaccine in Some Regions of China, 2012

Meningitis Morbidity and Mortality in China, 2008-2011

Lot Release Quantity of Meningococcal Vaccines in China by Type, 2007-2011

Suppliers and Lot Release Quantity of A Meningococcal Vaccine, 2007-2011

Suppliers and Lot Release Quantity of A+C Meningococcal Vaccine, 2007-2011

Suppliers and Lot Release Quantity of ACYW135 Meningococcal Vaccine in China, 2008-2011

Market Price of Meningococcal Vaccines in Some Regions of China, 2012

Consumption Forecast of A-MCV, A+C-MCV and ACYW135 Meningococcal Vaccine in China, 2012-2015E

Hepatitis A Morbidity and Mortality in China, 2008-2011

Hepatitis A Vaccine Lot Release Quantity in China, 2007-2011

Hepatitis A Vaccine Suppliers and Lot Release Quantity in China, 2007-2011

Market Price of Hepatitis A Vaccine in China, 2012

Consumption Forecast of Hepatitis A Vaccine in China, 2012-2015E

Influenza Morbidity and Mortality in China, 2008-2011

H1N1 Influenza Morbidity and Mortality in China, 2009-2011

Lot Release Quantity of Influenza Vaccine in China, 2007-2011

Suppliers and Lot Release Quantity of Influenza Split Vaccine in China, 2007-2011

Influenza Subunit Vaccine Suppliers and Lot Release Quantity in China, 2007-2011

Market Price of Influence Vaccine in China, 2012

Hib Vaccine Lot Release Quantity in China, 2007-2011

Hib Vaccine Suppliers and Lot Release Quantity in China, 2007-2011

Market Price of Hib Vaccine in Some Regions of China, 2012

Sales Volume Forecast of Hib Vaccine in China, 2012-2015E

Rabies Morbidity and Mortality in China, 2007-2011

Human Rabies Vaccine Lot Release Quantity in China, 2007-2011

Human Rabies Vaccine Lot Release Quantity in China by Type, 2007-2011

Human Vero Cell Rabies Vaccine Suppliers and Lot Release Quantity in China, 2007-2011

Human BHK Cell Rabies Vaccine Suppliers and Lot Release Quantity in China, 2007-2011

Market Price of Human Rabies Vaccine in Some Regions of China, 2012

Sales Volume Forecast of Human Rabies Vaccine in China, 2012-2015E

Varicella Vaccine Lot Release Quantity in China, 2007-2011

Suppliers and Lot Release Quantity of Varicella Vaccine in China, 2007-2011

Market Price of Varicella Vaccine in Some Regions of China, 2012

Lot Release Quantity of Pneumococcal Vaccine in China, 2007-2011

Suppliers and Lot Release Quantities of 7-valent and 23-valent Pneumococcal Vaccines in China, 2007-2011

Market Price of Pneumococcal Vaccines in Some Regions of China, 2012

DTP Vaccine Lot Release Quantity in China, 2007-2010

DTPa Vaccine Suppliers and Lot Release Quantity in China, 2007-2011

Poliomyelitis Vaccine Lot Release Quantity in China, 2007-2011

Poliomyelitis Vaccine Suppliers and Lot Release Quantity in China, 2007-2011

Export Volume & Value of Human Vaccine in China, 2009- 2011

Average Export Price of Human Vaccine in China, 2009- 2011

Export Destinations of Chinese Human Vaccines, 2011

Import Volume & Value of Human Vaccine in China, 2009-2011

Average Import Price of Human Vaccine in China, 2009-2011

Import Origins of Human Vaccine in China, 2011

Major Controlled Companies of Tiantan Biological and Their Revenue and Net Income

Revenue and Total Profit of Tiantan Biological, 2007-2012

Revenue of Tiantan Biological by Product, 2007-2011

Revenue of Tiantan Biological by Region, 2007-2011

Gross Margin of Tiantan Biological by Product, 2007-2011

Tiantan Biological's Procurement from Top 5 Suppliers and Proportion in Total Procurement, 2007-2011

Contribution of Top 5 Clients to Revenue of Tiantan Biological, 2007-2011

Top 5 Clients of Tiantan Biological and Their Contribution in Sales, 2011

Vaccine Revenue and Gross Margin of Tiantan Biological, 2007-2011

Lot Release Quantity and Proportion of Tiantan Biological's Vaccines, 2009-2011

Revenue and Total Profit of Hualan Biological, 2007-2011

Revenue of Hualan Biological by Industry, 2007-2011

Revenue Structure of Hualan Biological by Industry, 2007-2011

Revenue of Hualan Biological by Product, 2007-2011

Revenue Structure of Hualan Biological by Product, 2007-2011

Revenue of Hualan Biological by Region, 2007-2011

Revenue Structure of Hualan Biological by Region, 2007-2011

Gross Margin of Hualan Biological by Industry, 2007-2011

Gross Margin of Hualan Biological by Product, 2007-2011

Hualan Biological's Revenue from Top 5 Clients and % of Total Revenue, 2007-2011

Hualan Biological's Procurement from Top 5 Suppliers and % of Total Procurement, 2008-2011

Lot Release Quantity and Proportion of Hualan Biological's Vaccines, 2009-2011

Vaccine Revenue and Gross Margin of Hualan Biological, 2007-2011

Events Related to Vaccine Business of Hualan Biological, 2011-2012

Main Products of Zhifei Biological and Its Subsidiaries

Revenue and Profit of Zhifei Biological, 2007-2011

Revenue of Zhifei Biological by Product, 2010-2011

Lot Release Quantity and Proportion of Zhifei Biological's Vaccines, 2011

Revenue of Zhifei Biological by Region, 2009-2011

Gross Margin of Zhifei Biological by Product, 2007-2011

Zhifei Biological's Revenue from Top 5 Clients and % of Total Revenue, 2007-2011

R&D Costs and % of Total Revenue of Zhifei Biological, 2008-2011

New Vaccine Development Schedule of Zhifei Biological, 2011-2013

Released Vaccines and Capacity of Walvax Biotechnology

Revenue and Profit of Walvax Biotechnology, 2007-2011

Revenue of Walvax Biotechnology by Product, 2007-2011

Lot Release Quantity and Proportion of Walvax Biotechnology's Vaccines, 2009-2011

Revenue of Walvax Biotechnology by Region, 2010-2011

Gross Margin of Walvax Biotechnology, 2007-2011

Walvax Biological's Revenue from Top 5 Clients and Its Procurement from Top 5 Suppliers, 2007-2011

Name List and Revenue Contribution of Walvax Biological's Top 5 Clients, 2011

Name List and Procurement Contribution of Walvax Biological's Top 5 Suppliers, 2011

R&D Costs and % of Total Revenue of Walvax Biological, 2009-2011

On-going New Vaccine R&D of Walvax Biological, as of Dec. 31, 2011

Revenue and Profit of Sinovac Biotech Ltd., 2007-2011

Revenue of Sinovac Biotech Ltd. by Product, 2007-2011

Lot Release Quantity and Proportion of Sinovac Biotech Ltd.'s Vaccines, 2008-2011

Gross Margin of Sinovac Biotech Ltd., 2007-2011

R&D Costs and % of Total Revenue of Sinovac Biotech Ltd., 2007-2011

Revenue and Net Income of Liaoning Chengda, 2007-2011

Revenue of Liaoning Chengda by Industry, 2007-2011

Revenue Structure of Liaoning Chengda by Industry, 2007-2011

Revenue of Liaoning Chengda by Region, 2007-2011

Revenue Structure of Liaoning Chengda by Region, 2007-2011

Gross Margin of Liaoning Chengda by Industry, 2007-2011

Liaoning Chengda's Revenue from Top 5 Clients and % of Total Revenue, 2007-2011

Lot Release Quantity and Proportion of Chengda Biotechnology's Vaccines, 2009-2011

Human Rabies Vaccine Sales of Liaoning Chengda, 2009-2011

Vaccine Gross Margin of Liaoning Chengda, 2009-2011

Vaccine Sales and Total Profit of Liaonig Chengda, 2009-2011

Revenue and Total Profit of Changchun BCHT, 2009-2011

Lot Release Quantity and Proportion of Changchun BCHT's Vaccines, 2009-2011

Lot Release Quantity and Proportion of Changchun Changsheng's Vaccines, 2008-2011

Vaccines of Zhejiang Tianyuan Bio-Pharmaceutical

Lot Release Quantity and Proportion of Zhejiang Tianyuan Bio-Pharmaceutical's Vaccines

2008-2011

Lot Release Quantity and Proportion of Kangtai Biological's Vaccines, 2008-2011

Lot Release Quantity and Proportion of Hissen Bio-pharm's Vaccines, 2009-2011

Vaccine Projects of Hissen Bio-pharm, 2011

More  

Check our  

Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker